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SUMMARY
Obesity is a major risk factor for the development
of metabolic syndrome and type 2 diabetes. How
obesity contributes to metabolic syndrome is un-
clear. Free fatty acid (FFA) activation of a non-recep-
tor tyrosine kinase (SRC)-dependent cJun NH2-ter-
minal kinase (JNK) signaling pathway is implicated
in this process. However, the mechanism that medi-
ates SRC-dependent JNK activation is unclear. Here,
we identify a role for the scaffold protein JIP1 in SRC-
dependent JNK activation. SRC phosphorylation of
JIP1 creates phosphotyrosine interaction motifs
that bind the SH2 domains of SRC and the guanine
nucleotide exchange factor VAV. These interactions
are required for SRC-induced activation of VAV
and the subsequent engagement of a JIP1-tethered
JNK signaling module. The JIP1 scaffold protein,
therefore, plays a dual role in FFA signaling by
coordinating upstream SRC functions together with
downstream effector signaling by the JNK pathway.
INTRODUCTION
Human obesity is a worldwide health problem that is associated
with metabolic syndrome and the development of insulin resis-
tance and type 2 diabetes (Flegal et al., 2013). Effects of obesity
on metabolic syndrome are mediated, in part, by increased
amounts of saturated free fatty acid (FFA) in the blood (Kahn
et al., 2006). A key signaling mechanism that is activated by
FFA is the cJun NH2-terminal kinase (JNK) stress response
pathway (Davis, 1994, 2000). Studies using JNK-deficient mice
demonstrate that JNK signaling is required for the development
of obesity and insulin resistance (Sabio and Davis, 2010). Conse-
quently, components of the JNK signaling pathway represent
potential targets for the design of drugs that may be useful for
the treatment of metabolic syndrome (Sabio and Davis, 2010).
The mechanism of JNK activation caused by FFA is unclear.
Recent studies have identified the non-receptor tyrosine kinase
SRC (Holzer et al., 2011), the small GTPase RAC1 (Sharma
et al., 2012), and the mixed-lineage protein kinase (MLK) family
of MAP kinase kinase kinase (MAP3K) (Craige et al., 2016;
Jaeschke and Davis, 2007; Kant et al., 2013; Sharma et al.,
2012) as components of an FFA-stimulated signaling pathway
that activates JNK. However, the mechanism that mediates
signaling has not been established. Here, we report that the scaf-
fold protein JIP1 can serve to link SRC, RAC1, and MLK in an
FFA-stimulated signaling pathway.
RESULTS
JIP1 Is Required for FFA-Stimulated SRC Activation and
Redistribution to Lipid Rafts
The scaffold protein JIP1 binds SRC family members (Kennedy
et al., 2007; Nihalani et al., 2007) and is implicated in the MLK
pathway that leads to JNK activation (Jaeschke et al., 2004;
Morel et al., 2010; Whitmarsh et al., 1998, 2001). It is established
that FFA causes SRC redistribution to Triton-insoluble lipid rafts
(Holzer et al., 2011). To test whether JIP1 might contribute to
SRC function, we examined whether FFA treatment caused a
similar redistribution of JIP1. This analysis demonstrated
increased amounts of JIP1, SRC, and activated pY416-SRC in
the Triton-insoluble fraction of cells exposed to FFA (Figure 1A).
Moreover, immunofluorescence analysis of Triton-permeabi-
lized cells demonstrated co-localization of JIP1 and SRC in
FFA-treated cells (Figure 1B).
The co-regulation of SRC and JIP1 (Figures 1A and 1B) indi-
cated that JIP1 (encoded by theMapk8ip1 gene) may contribute
to FFA signaling. We, therefore, compared the response of
wild-type (WT) and Mapk8ip1/ cells to FFA. Treatment of WT
primary murine embryo fibroblasts (MEFs) with FFA caused
JNK activation and the redistribution of SRC and activated
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pY416-SRC to lipid rafts (Figures 1C and 1D). In contrast,
Mapk8ip1/ MEFs were resistant to FFA-stimulated JNK acti-
vation and SRC redistribution to Triton-insoluble lipid rafts.
Together, these data demonstrate that JIP1 is required for the
regulation of both SRC and JNK by FFA.
The requirement of JIP1 for FFA-stimulated JNK activation
(Figure 1C) may represent a general role of JIP1 in JNK signaling.
We, therefore, compared JNK activation inWT andMapk8ip1/
MEFs in response to the inflammatory cytokine tumor necrosis
factor a (TNF-a). This analysis demonstrated that TNF-a causes
similar JNK activation in control and JIP1-deficient cells (Fig-
ure S1). JIP1, therefore, plays a selective role in JNK activation,
including FFA signaling.
The JIP1 JNK-Binding Domain Is Required for HFD-
Induced Insulin Resistance
To test whether JIP1-mediated JNK activation is relevant to the
metabolic stress response in vivo, we established mice lacking
Figure 1. JIP1 Is Required for Palmitate-Induced Localization of SRC to Lipid Rafts
(A and B) RIN5F cells expressing EE-tagged JIP1 were treated with fatty-acid-free BSA or palmitate/BSA (FFA). The total cell lysate and the Triton-insoluble lipid
raft fraction were examined by immunoblot analysis (A). Cells permeabilized with Triton X-100 and fixed were examined by immunofluorescence analysis (B).
Scale bar, 10 mm.
(C and D) WT and Mapk8ip1/ MEFs were treated with BSA or FFA. An Optiprep 40%–30%–5% step gradient separated raft and non-raft fractions for ex-
amination by immunoblot analysis (C). The total cell lysate and the Triton-insoluble lipid raft fraction were examined by immunoblot analysis (D).
See also Figure S1.
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the JNK-binding domain of JIP1 (Mapk8ipDJBD/DJBDmice, desig-
nated as JIP1DJBD mice). The core of the JNK-binding domain
(Leu160-Asn161-Leu162) binds a hydrophobic pocket on JNK
(Heo et al., 2004; Whitmarsh et al., 1998) and is required for
JIP1-mediated JNK activation (Whitmarsh et al., 1998). This
core motif was replaced with Gly160-Arg161-Gly162 in JIP1DJBD
mice (Figure S2). Control studies demonstrated that MEF
derived from JIP1DJBD mice were resistant to FFA-stimulated
JNK activation (Figure 2A). Comparison of WT and JIP1DJBD
mice fed a chow diet (ND) or a high-fat diet (HFD) demonstrated
that the HFD-induced insulin intolerance detected in WT mice
was suppressed in JIP1DJBD mice (Figure 2B). The improved in-
sulin tolerance of HFD-fed JIP1DJBD mice was associated with
markedly decreased HFD-induced hyperinsulinemia, compared
with WT mice (Figure 2C).
Hyperinsulinemic-euglycemic clamp analysis of glucose infu-
sion rates confirmed that HFD-fed JIP1DJBD mice were more in-
sulin sensitive than HFD-fed WT mice (Figure 2D). Moreover, the
HFD-fed JIP1DJBD mice exhibited decreased hepatic glucose
production (Figure 2E), increased hepatic insulin action (Fig-
ure 2F), and increased whole-body glucose turnover (Figure 2G),
compared with HFD-fed WT mice. These phenotypes were
associated with increased energy expenditure and decreased
obesity (Figure S3), reduced adipose tissue hypertrophy (Figures
S4A and S4B), and reduced hepatic steatosis (Figure S4C). This
protection of HFD-fed JIP1DJBD mice against obesity and insulin
resistance is similar to that detected in JNK-deficient mice
(Sabio and Davis, 2010). Together, these data establish that
JIP1-mediated JNK activation contributes to the HFD-induced
metabolic stress response in vivo.
VAV, RAC1, MLK, and MKK7 Contribute to JIP1-
Mediated JNK Activation
To examine the mechanism of JIP1-mediated JNK activation
caused by exposure of cells to saturated FFA, we tested the
role of JNK pathway components that interact with JIP1,
including the MAP2K isoform MKK7 and the MLK family of
MAP3K (Whitmarsh et al., 1998). Analysis of WT andMap2k7/
MEFs demonstrated that MKK7 is required for FFA-stimulated
JNK activation (Figure 3A). To test the role of the MLK group of
MAP3K, we examined the effect of dual deficiency of MLK2
plus MLK3, the major MLK family members expressed by
MEFs (Kant et al., 2011). Comparison of WT and Map3k10/
Map3k11/ MEFs demonstrated that MLK protein kinases are
essential for FFA-stimulated JNK activation (Figure 3B). In
contrast, we found that MLK protein kinases were not required
for FFA-stimulated SRC and activated SRC redistribution to lipid
rafts (Figure 3C). This analysis identifies SRC as an upstream
component of the JIP1-mediated MLK-MKK7-JNK signaling
pathway that is activated by FFA.
MLK isoforms can be activated by the RHO family GTPase
RAC1 by binding to a conserved MLK CRIB domain (Teramoto
Figure 2. JIP1-Mediated JNK Activation Promotes HFD-Induced Insulin Resistance
(A) Control (BSA) and palmitate (C16)-stimulated (for 16 hr) WT and JIP1DJDB MEFs were examined by immunoblot analysis.
(B) WT and JIP1DJBD mice were fed a chow diet (ND) or an HFD (for 16 weeks) and examined with an insulin tolerance test. The time course of insulin-stimulated
glucose clearance is presented (mean ± SEM; n = 10; *p < 0.05).
(C) The blood concentration of insulin was measured by ELISA (mean ± SEM; n = 10; **p < 0.01).
(D–G) The glucose infusion rate (D), clamp hepatic glucose production (E), hepatic insulin action (F), and whole-body glucose turnover (G) measured by
hyperinsulinemic-euglycemic clamp analysis (mean ± SEM; n = 8; *p < 0.05; **p < 0.01).
See also Figures S2, S3, and S4.
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Figure 3. VAV, RAC1, MLK, and MKK7 Contribute to JIP1-Mediated JNK Activation
(A and B) WT andMap2k7/MEFs (A) orMap3k10/Map3k11/MEFs (B) were treated (for 16 hr) without (BSA) or with palmitate/BSA (FFA) and subsequently
examined by immunoblot analysis.
(C) The lipid raft fraction of WT and Map3k10/ Map3k11/ MEFs treated (for 4 hr) without (BSA) or with palmitate/BSA (FFA) was examined by immunoblot
analysis.
(D) WT and Map3k10/ Map3k11-DCRIB/DCRIB MEFs were treated with BSA or FFA/BSA (for 16 hr) and examined by immunoblot analysis.
(E) WT and Vav1/ Vav2/ Vav3/ (Vav/) cells were treated with BSA or FFA/BSA (for 16 hr) and examined by immunoblot analysis.
(F and G) WT and Mapk8ip1/ MEFs were treated with BSA or FFA. JIP1 immunoprecipitates (F) and isolated lipid rafts (G) were examined by immunoblot
analysis.
(H)WT andVav1/ Vav2/ Vav3/ (Vav/) cells were transducedwith a retrovirus expressing EE-tagged JIP1. The cells were treatedwith BSA or FFA/BSA (for
4 hr) and examined by immunoblot analysis of cell lysates and isolated lipid rafts.
(I–K) SFY fibroblasts and SFY cells complementedwith SRC (SFY +SRC) fibroblastswere transducedwith a retrovirus expressing EE-tagged JIP1. The cells were
treated with BSA or FFA/BSA and examined by immunoblot analysis of cell lysate (I), JIP1 immunoprecipitates (J), or isolated lipid rafts (K).
(L) Constitutively activated SRC (SRCY529F) and SRC expression plasmids were used in transfection assays with WT and Map3k10/ Map3k11/ MEFs. Cell
lysates were prepared at 24 hr post-transfection and examined by immunoblot analysis.
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et al., 1996). To test whether this CRIB-mediated mechanism
contributes to FFA-stimulated JNK activation, we examined
the effect of an inactivating mutation in the MLK3 CRIB
domain (Ile492 Ser493 replaced with Ala492 Ala493) in the context
of deficiency of the redundant isoform MLK2 (Kant et al.,
2011). Comparison of WT andMap3k10/ Map3k11DCRIB/DCRIB
MEFs demonstrated that the MLK CRIB domain is essential
for FFA-stimulated JNK activation (Figure 3D). This mechanism
is consistent with the observation that RAC1 activation is
required for the regulation of JNK activity by FFA (Sharma
et al., 2012).
The exchange factor VAV has been implicated in JNK activa-
tion (Crespo et al., 1996; Kant et al., 2011). To test whether
VAV contributes to FFA-stimulated JNK activation, we
compared JNK activity in WT and VAV-deficient (Vav1/
Vav2/ Vav3/) cells. This analysis demonstrated that VAV is
required for FFA-stimulated JNK activation (Figure 3E). More-
over, FFA treatment caused an interaction between VAV and
JIP1 that was detected by co-immunoprecipitation analysis
(Figure 3F). FFA treatment also caused JIP1-dependent redistri-
bution of VAV to lipid rafts (Figure 3G), although VAV was not
required for the lipid raft association of JIP1 (Figure 3H).
FFA Causes SRC-Mediated Tyrosine Phosphorylation
of JIP1 and VAV
The interaction between VAV and JIP1 was associated with FFA-
stimulated tyrosine phosphorylation of both proteins (Figure 3F).
The role of JIP1 tyrosine phosphorylation is unclear, but it is
established that tyrosine phosphorylation of VAV increases GTP/
GDP exchange activity on RAC1 (Crespo et al., 1997). To examine
the mechanism of FFA-stimulated tyrosine phosphorylation of
JIP1 and VAV, we tested the potential role of SRC family tyrosine
kinases. These studies were performed using Src/ Fyn/
Yes/ (SFY) cells. Treatment of SFY cells with FFA did not cause
JNK activation (Figure 3I) or tyrosine phosphorylation of JIP1 and
VAV (Figure 3J). In contrast, complementation analysis demon-
strated that the expression of SRC restored both JNK activation
and tyrosine phosphorylation of both JIP1 and VAV in FFA-treated
cells (Figures 3I and 3J). Furthermore, SRC was required for JIP1
redistribution to lipid rafts (Figure 3K). SRC family protein kinases,
therefore, function as components of the JNK signaling pathway
activated by treatment of cells with FFA.
To test whether SRC-mediated activation of JNK is mediated
by theMLK pathway, we expressed constitutively activated SRC
(SRCY529F) inWT andMap3k10/Map3k11/MEFs. Activated
SRC caused JNK activation selectively in the WT MEFs (Fig-
ure 3L). These data demonstrate that the MLK pathway is an
essential mediator of SRC-induced JNK activation.
Previous studies of JIP1 tyrosine phosphorylation have impli-
cated roles for both ABL (Dajas-Bailador et al., 2008) and SRC
(Kennedy et al., 2007; Nihalani et al., 2007). To confirm the role
of SRC in FFA-stimulated tyrosine phosphorylation of JIP1, we
examined the effect of drugs that selectively inhibit ABL and
SRC. This analysis demonstrated that theSRC-selective inhibitor
AZD0530, but not the ABL-selective inhibitor Gleevec, prevented
FFA-stimulated tyrosine phosphorylation of JIP1 (Figure 4A).
These data confirm that SRC family tyrosine kinases contribute
to FFA-stimulated tyrosine phosphorylation of JIP1 (Figure 4A).
Tyrosine Phosphorylation of JIP1 Is Required for FFA-
Stimulated JNK Activation
JIP1 is extensively phosphorylated (D’Ambrosio et al., 2006),
includingonsitesof tyrosine (Y278, Y409, andY427) phosphorylation
(Dajas-Bailador et al., 2008; Kennedy et al., 2007; Nihalani et al.,
2007). This phosphorylation may create sites of interaction for
signaling proteins with SH2 domains. Indeed, phosphotyrosine-
dependent binding of JIP1 to the SH2 domain of SRC family
proteins has been identified (Kennedy et al., 2007; Nihalani
et al., 2007). A similar interaction might account for the binding
of JIP1 to VAV. To test SH2 domain binding to JIP1, we examined
the interaction of JIP1 with the SH2 domains of SRC and VAV2.
This analysis demonstrated that JIP1 from FFA-treated cells
bound to SRC-SH2 and VAV2-SH2 (Figures 4B and 4C). In
contrast, JIP1 from control cells did not bind VAV2-SH2, but a
low level of interaction with SRC-SH2 was detected (Figures 4B
and 4C).
To examine the role of JIP1 tyrosine phosphorylation in JNK
activation caused by saturated FFA, we performed complemen-
tation analysis using Mapk8ip1/ MEFs expressing WT or
mutated JIP1 proteins. Two sites of tyrosine phosphorylation
on JIP1 (pY409DNC and pY427EEA) are similar to the optimal
sequence (pYEEI) for phosphotyrosine binding by the SRC-
SH2 domain (Songyang et al., 1993). Mutational analysis indi-
cated that Y409 and Y427 serve partially redundant functions.
We, therefore, examined the function of JIP1 with dual mutation
at Y409 plus Y427. This analysis demonstrated that tyrosine phos-
phorylation of JIP1 was increased when cells were treated with
FFA (Figure 4D). In contrast, phosphotyrosine was not detected
on the mutated JIP1Y409/427F protein (Figure 4D). Co-immuno-
precipitation analysis demonstrated that the interaction of SRC
with JIP1 in control and FFA-treated cells was suppressed in
studies with the mutated JIP1Y409/427F protein (Figure 4D).
Furthermore, the FFA-stimulated redistribution of JIP1 and
SRC to lipid rafts depends on these sites of JIP1 tyrosine phos-
phorylation (Figure 4E). These data indicate that Y409 and Y427
are required for FFA-stimulated JIP1 tyrosine phosphorylation
and SRC binding.
One site of tyrosine phosphorylation on JIP1 (pY278LTP) is
similar to the optimal sequence (pYMEP) for phosphotyrosine
binding by the VAV SH2 domain (Songyang et al., 1994). Com-
parison of Mapk8ip1/ MEFs expressing WT and JIP1Y278F
proteins demonstrated that treatment with FFA promoted the
co-immunoprecipitation of VAV with JIP1 and that this interac-
tion was dependent on Y278 (Figure 4F). The phosphorylation
site Y278 is, therefore, required for the FFA-induced interaction
of JIP1 and VAV.
To test the requirement of JIP1 tyrosine phosphorylation for
FFA-stimulated JNK activation, we compared Mapk8ip1/
MEFs expressing WT JIP1 and mutated JIP proteins (JIP1Y278F
or JIP1Y409/427F). This analysis demonstrated that expression
of WT JIP1 in Mapk8ip1/ MEFs restored FFA-stimulated JNK
activation (Figure 4G). In contrast, FFA-stimulated JNK activa-
tion was not detected in Mapk8ip1/ MEFs expressing
JIP1Y278F or JIP1Y409/427F (Figure 4G). Together, these data
indicate that the tyrosine-phosphorylation-dependent interac-
tion of JIP1 with SRC and VAV is required for FFA-stimulated
JNK activation (Figure 4H).
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DISCUSSION
An understanding of the physiological mechanism of FFA-stimu-
lated JNK activation has remained elusive, because several po-
tential pathways have been implicated. Indeed, it is likely that
FFA-stimulated JNK activation may occur by more than one
mechanism in vivo, possibly in a cell-type- and context-specific
manner. These potential mechanisms include: (1) the FFA-
induced endoplasmic reticulum unfolded protein response (Fu
et al., 2012); (2)FFA ligandbinding toG-protein-coupled receptors
(Alvarez-Curto and Milligan, 2016; Moran et al., 2016); (3) FFA
metabolismandaccumulation of signaling lipids, includingdiacyl-
glycerol, ceramide, and sphingosine-1-phosphate (Hu et al.,
2009; Montell et al., 2001; Schmitz-Peiffer et al., 1999); (4) FFA-
stimulated NBR1-MEKK3 signaling (Hernandez et al., 2014); and
(5) FFA-stimulated lipid raft signaling (Holzer et al., 2011). It is
also possible that FFA causes JNK activation as part of a general-
ized lipotoxic stress response (Neuschwander-Tetri, 2010).
Here, we examined the lipid raft signaling mechanism of FFA-
stimulated JNK activation (Holzer et al., 2011). Previous studies
Figure 4. Tyrosine Phosphorylation of JIP1 Is Necessary for Palmitate-Induced Tethering of SRC/VAV and JNK Activation
(A)Mapk8ip1/MEFs were transducedwith an empty retroviral vector (control) or with a retroviral vector that expresses T7-tagged JIP1. TheMEFs were treated
with or without Gleevec (1 mM) or AZD0530 (10 nM) for 30 min before addition of BSA or FFA/BSA (for 4 hr). Cell lysates and JIP1 immunoprecipitates were
examined by immunoblot analysis.
(B andC) His6-SRC-SH2 (B) and His6-VAV2-SH2 (C) immobilized on nickel beads were incubated with extracts prepared fromWT andMapk8ip1
/MEFs treated
with BSA or FFA (for 4 hr). Bound proteins were detected by immunoblot analysis using antibodies to His6 and JIP1.
(D–F) Mapk8ip1/ MEFs were transduced with an empty retroviral vector (Control) or with a retroviral vector that expresses T7-tagged JIP1, JIP1Y278F, or
JIP1Y409/427F. The MEFs were treated with BSA or FFA/BSA (for 4 hr). JP1 immunoprecipitates (D), isolated lipid rafts (E), and cell lysates (F) were examined by
immunoblot analysis.
(G)Mapk8ip1/MEFs (Control) andMapk8ip1/MEFs expressing T7-tagged JIP1, JIP1Y278F, or JIP1Y409/427F were treatedwith BSA or FFA/BSA (for 16 hr), and
cell lysates were examined by immunoblot analysis.
(H) Schematic illustration of JIP1-mediated activation in response to exposure to FFA.
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have demonstrated roles for SRC (Holzer et al., 2011), RAC1
(Sharma et al., 2012), and the MLK group of MAP3K (Jaeschke
and Davis, 2007; Kant et al., 2013). While VAV can load GTP
on RAC1 and activate MLK (Teramoto et al., 1996), the role of
SRC in this signaling pathway has not been established (Holzer
et al., 2011).
Our analysis demonstrates that the scaffold protein JIP1 plays
a dual role in FFA signaling by co-ordinating upstream SRC func-
tions together with downstream effector signaling by the JNK
pathway (Figure 4H). SRC phosphorylation of JIP1 creates phos-
photyrosine interactionmotifs that bind the SH2 domains of SRC
and the guanine nucleotide exchange factor VAV. These interac-
tions are required for SRC-induced tyrosine phosphorylation and
activation of VAV and the subsequent engagement of a JIP1-
tethered JNK signaling module (Figure 4H). It is likely that this
mechanism contributes to physiological regulation, because de-
fects in JIP1 (Jaeschke et al., 2004; Morel et al., 2010), including
disruption of the JIP1 JNK-binding site (Figure 2), strongly sup-
press the consequences of HFD consumption by mice.
The interaction of JIP1 with signaling molecules provides an
opportunity for the design of small molecules to disrupt FFA-
stimulated JNK activation. This approach has been used to iden-
tify drugs that target the JNK/JIP1 interaction (Chen et al., 2009;
Stebbins et al., 2008) but could be extended to the new interac-
tions identified by our study. Since JNK has many physiological
functions, drugs that target the JIP1 scaffold proteinmay provide
greater selectivity for suppression of JNK activation caused by
metabolic stress. Such drugs may be useful for the treatment
of obesity-induced metabolic stress, including metabolic syn-
drome and type 2 diabetes (Kaneto et al., 2004).
EXPERIMENTAL PROCEDURES
Mice
C57BL/6J mice (stock number 000664) and Rosa-CreERT mice (stock number
00487) (Badea et al., 2003) were obtained from The Jackson Laboratory.
We have previously described Mapk8ip1/ mice (Whitmarsh et al., 2001),
Map2k7LoxP/LoxP mice (H€ubner et al., 2012), Map3k10/ mice (Kant et al.,
2011), Map3k11/ mice (Brancho et al., 2005), Map3k11DCRIB/DCRIB mice
(Kant et al., 2011), and Vav1/ Vav2/ Vav3/ mice (Fujikawa et al., 2003)
on a C57BL/6J strain background.
Mice with a defect in the JNK-binding domain of JIP1 (replacement of
Leu160-Asn161-Leu162 with Gly160-Arg161-Gly162) were established using
homologous recombination in embryonic stem cells (ESCs) using standard
methods (Figure S2). The mutated allele was designated Mapk8ip1DJBD.
Briefly, a targeting vector was constructed (Figure S2A). This targeting vector
was designed to introduce point mutations in exon 3 of theMapk8ip1 gene that
create the DJBD mutation and also the introduction of an EagI restriction site
(Figures S2A and S2B). The targeting vector was also designed to introduce a
floxed NeoR cassette in intron 3 (Figure S2A). TC1 ESCs (strain 129svev) were
electroporated with this vector and selected with 200 mg/mL G418 (Invitrogen)
and 2 mM gancyclovir (Syntex). ESC clones with the floxed NeoR cassette
correctly inserted in intron 3 were identified by Southern blot analysis (Fig-
ure S2C). These ESCs included clones without (genotype +/NeoR-
Mapk81p1WT) and with (genotype +/NeoR-Mapk8ip1DJBD) the DJBD mutation
in exon 3 (Figure S2D). These ESCswere injected into C57BL/6J blastocysts to
create chimeric mice that were bred to obtain germline transmission of the
targetedMapk8ip1 allele. The floxed NeoR cassette was excised using Cre re-
combinase. Themice used in this study were backcrossed (ten generations) to
the C57BL/6J strain (The Jackson Laboratory).
Male mice (8–10 weeks old) were fed a chow diet (Iso Pro 3000, Purina) or an
HFD (F3282, Bioserve). Mice were housed in a facility accredited by the Amer-
ican Association for Laboratory Animal Care. The Institutional Animal Care and
Use Committee of the University of Massachusetts Medical School approved
all studies using animals.
Genotype Analysis
PCR analysis of genomic DNA was used to detect Mapk8ip1 (Whitmarsh
et al., 2001); Map3k10 (Kant et al., 2011); Map3k11 (Brancho et al., 2005);
Map3k11DCRIB (Kant et al., 2011); and Vav1, Vav2, and Vav3 (Fujikawa
et al., 2003) alleles. TheMapk8ip1DJBD allele was detected using three different
assays. First, Southern blot analysis of HindIII-restricted genomic DNA
was performed by probing with a 500-bp fragment of the Mapk8ip1 gene
that was isolated by PCR using the primers 50-CACATCTTGTGTGCT
CAATCCG-30 and 50-GTTCTGGCTTCTGATACTGAACCC-30. The Mapk8ip+
and Mapk8ip1DJBD alleles were detected as 11.9-kb and 6.6-kb genomic
fragments, respectively (Figure S2C). Second, a PCR assay was used using
the primers 50-GCAAGCTGGGAAGATGACTTTATG-30 and 50-AGACTGC
CTTGGGAAAAGCG-30 and EagI digestion to yield 2.1-kb (Mapk8ip+) or
1.175-kb plus 0.925-kb DNA fragments (Mapk8ip1DJBD) (Figure S2D).
Third, backcrossed mice were genotyped by PCR using the primers
50-CCAAGTTGTGTGTGGAGAGCTTG-30 and 50-GCAGATGTTGGAGGAAGA
AGCAC-30 to yield a 400-bp DNA fragment (Mapk8ip1+) or a 450-bp DNA frag-
ment (Mapk8ip1DJBD) (Figure S2E).
Plasmids
The retroviral vector pBABE-puro (Morgenstern and Land, 1990) was obtained
from Addgene (plasmid #1764). The Mapk8ip1b cDNA was modified by
insertion of a sequence encoding the T7 epitope tag between codons 1 and
2 (Whitmarsh et al., 1998) and was cloned as a blunt-end fragment into the
EcoRI site of pBABE-puro. Point mutations in the Mapk8ip1b cDNA were
made using primers 50-CGACTGAGGAGATCTTCCTGACCCCAGTGC-30 and
50-GCTGACTCCTCTAGAAGGACTGGGGTCACG-30 (for JIP1bY278F) and
two pairs of primers 50-CTCTGCCACTGTCTTTGACAACTGTGCCTC-30 plus
50-GAGACGGTGACAGAAACTGTTGACACGGAG-30 and 50-GCCATTGGTGA
GGAGTTTGA GGAGGCCCCTC-30 plus 50-CGGTAACCACTCCTCAAACT
CCTCCGGGGAG-30 (for JIP1bY409/427F) with a QuikChange II XL Kit (Strata-
gene) and confirmed by DNA sequence analysis. The mammalian expression
vectors for SRC (plasmid #26983) and constitutively active SRCY529F (plasmid
#17686) were obtained from Addgene. Bacterial expression vectors for His6-
SRC-SH2 and His6-VAV-SH2 (pET28 sacB AP vector with kanamycin resis-
tance) were purchased from Open BioSystems (#OHS4902_SH2).
Cell Culture
SFY fibroblasts, complementedwithout andwith SRC (Klinghoffer et al., 1999),
were obtained from the American Type Culture Collection (CRL2459 and
CRL2498). RIN5F cells expressing Glu-Glu-tagged JIP1b have been described
previously (Standen et al., 2009). Primary WT MEFs, Mapk8ip1/ MEFs,
Mapk8ip1DJBD/DJBD MEFs, Map3k10/ Map3k11/ MEFs, and Map3k10/
Map3k11DCRIB/DCRIB MEFs were isolated and cultured in vitro (Kant
et al., 2011). Map2k7/ MEFs were prepared by treating Rosa-CreERT
Map3k7LoxP/LoxPMEFs with 1 mM4-hydroxytamoxifen (24 hr). MEF transduced
with pBABE-puro retroviral vectors were selected by incubation (24 hr) with
10 mg/mL puromycin (Lamb et al., 2003). Studies of primary MEFs were per-
formed using cells between passages 3 and 5. Cells were transferred to
DMEM supplemented with 0.5% fetal bovine serum (Life Technologies) and
incubated (1 hr) prior to treatment with 0.5% BSA or 0.75 mM palmitate/
0.5% (w/v) BSA. Cells were treated with 1 mM imatinib (Gleevec) or 10 nM Sar-
acatinib (AZD0530) (Selleck Chemicals). Plasmid transfection assays were
performed using Lipofectamine (Life Technologies).
Lipid Raft Isolation
Methods for detergent-dependent lipid raft isolation were described earlier
(Holzer et al., 2011; Lingwood and Simons, 2007). Briefly, cells were pre-
pared using Triton lysis buffer (20 mM Tris [pH 7.4], 1% Triton X-100,
10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM b-glycerophosphate,
1 mM sodium orthovanadate, 1 mM PMSF, and 10 mg/mL of aprotinin
plus leupeptin), sheared with a 25G needle and incubated at 4C
(30 min). Optiprep (Sigma) 40%–30%–5% step gradients were prepared
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prior to flotation of the cell lysate on the step gradient and centrifugation
(16 hr at 260,000 3 g). Raft and non-raft fractions were collected and exam-
ined by protein immunoblot analysis.
Immunoblot Analysis
Cell extracts were prepared using Triton lysis buffer (20 mM Tris [pH 7.4], 1%
Triton X-100, 10%glycerol, 137mMNaCl, 2mMEDTA, 25mM b-glycerophos-
phate, 1 mM sodium orthovanadate, 1 mM PMSF, 10 mg/mL aprotinin and leu-
peptin) for 20 min at ice. Triton-soluble and -insoluble fractions were prepared
by centrifugation at 13,000 rpm (10 min) and examined by protein immunoblot
analysis. Primary antibodies were obtained from Cell Signaling Technology
(MLK3, pJNK, SRC, and pY416-SRC), Covance (Glu-Glu tag), Life Technolo-
gies (JNK, Flotillin1, and JIP1), Millipore (T7 tag), Santa Cruz Biotechnology
(VAV2 and Flotillin2), and Sigma (a-Tubulin). Immune complexes were de-
tected by enhanced chemiluminescence (New England Nuclear) using an
ImageQuant LAS 4000 (General Electric).
Immunoprecipitation
Cell extracts were prepared using NP-40 lysis buffer (150 mM NaCl, 50 mM
Tris [pH 8.0], 5 mM EDTA, 1% NP-40, 1 mM sodium orthovanadate, 1 mM
PMSF, 10 mg/mL aprotinin and leupeptin) and incubated (5 hr at 4C) with
10 mg control nonimmune rabbit immunoglobulin G (IgG) (Santa Cruz Biotech-
nology) or 10 mg rabbit antibodies to theGlu-Glu tag (Covance) or JIP1 (Yasuda
et al., 1999). Immune complexes isolated using protein G sepharose (Sigma)
were washed (five times) with lysis buffer.
In Vitro SH2 Domain Interaction Assays
Bacterial expression of His6-SRC-SH2 and His6-VAV-SH2 was induced
with 1 mM isopropyl b-D-1-thiogalactoside (IPTG) (3 hr, 37C). The bacteria
were lysed by sonication in Buffer X (20 mM Tris [pH 7.4], 1 M NaCl, 0.2 mM
EDTA, 0.2 mMEGTA, 1mMDTT, 1mMPMSF, 10 mg/mL aprotinin and leupep-
tin). The soluble extract was clarified by centrifugation. The supernatant was
incubated (1 hr at 4C) with 20 mL nickel magnetic beads (GE Healthcare Life
Sciences, #28-9781-19 AB). The beads were washed with Buffer X and then
incubated with extracts (100 mg protein) prepared from WT and Mapk8ip1/
MEFs using Triton lysis buffer (20mMTris [pH 7.4], 1%Triton X-100, 10%glyc-
erol, 137 mM NaCl, 2 mM EDTA, 25 mM b-glycerophosphate, 1 mM sodium
orthovanadate, 1 mM PMSF, 10 mg/mL of aprotinin and leupeptin). The beads
were washed with Triton lysis buffer, and bound proteins were examined by
immunoblot analysis.
Immunofluorescence
Cells grown on glass coverslips were treated (1 min) at room temperature (RT)
with 0.5% Triton X-100 in PBS and then fixed by incubation at 4C in 4% para-
formaldehyde (30 min). The coverslips were incubated (1 hr) with blocking
buffer (3% [w/v] BSA in PBS) at RT and then incubated (1 hr) with primary an-
tibodies diluted in blocking buffer at RT. The primary antibodies to the Glu-Glu
epitope tag (Covance) and SRC (Cell Signaling Technology) were used. The
coverslips were washed with 0.5% Tween 20/PBS. The primary antibodies
were detected by incubation with anti-mouse or anti-rabbit immunoglobulin
conjugated to Alexa Fluor 488 or 546 (Life Technologies). Fluorescence was
visualized using a Leica TCS SP2 confocal microscope equipped with a
405-nm diode laser.
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